Keyword: Magenta Therapeutics
Fresh off a $55.5 million round, IFM Therapeutics snagged a new chief scientific officer. Michael Cooke, Ph.D., joins from stem cell biotech Magenta.
The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
Abeona fires CEO Carsten Thiel; MHRA CEO to leave in wake of Brexit; Lilly CMO to lead Brickell Bio; and Janssen's discovery head joins Incyte.
Jason Ryan has hopped from Foundation to Medicine to Magenta Therapeutics after playing a key role in Foundation’s $2.4 billion buyout by Roche.
Magenta’s MGTA-456 hit efficacy targets in the first patients from a phase 2 trial that will drop at ASH next month, but with a question about safety.
No fewer than five biotech IPOs debuted Thursday, raising more than $460 million and with more in the offing if underwriters take up further options.
Coming off the back of a healthy financing round just six weeks ago, stem cell biotech Magenta Therapeutics now wants more, and it wants to go public.
Atara hires ex-Genentech SVP to lead R&D, Semma names former Novartis CAR-T developer as CEO, and GSK's CFO heads for the exit.
Semma Therapeutics named Bastiano Sanna, formerly of Novartis’ cell and gene therapy unit and Magenta Therapeutics, as its president and CEO.
Celgene COO Scott Smith resigns, ex-Kite leaders Belldegrun and Chang form new CAR-T shop, GSK Dermatology exec jumps to Dermavant.